Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anixa Biosciences, Inc. - Common Stock (NQ:ANIX)

3.599 +0.179 (+5.24%)
Streaming Delayed Price Updated: 3:21 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Anixa Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent
Anixa secures USPTO patent for its breast cancer vaccine using α-lactalbumin, enhancing its IP portfolio and expanding future immunotherapy options. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines
Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer vaccines, with U.S. trials planned. 
Via Benzinga
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine
Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and advancing its clinical development. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Recap: Anixa Biosciences Q1 Earnings
Via Benzinga
6 Analysts Have This to Say About Anixa Biosciences
Via Benzinga
The Latest Analyst Ratings for Anixa Biosciences
Via Benzinga
Expert Ratings for Anixa Biosciences
Via Benzinga
This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying
Via Benzinga
EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy
FDA Approves Anixa Biosciences' Ovarian Cancer CAR-T Therapy for Individual Patient Trial. Moffit Cancer Center receives approval for a second dose in an ongoing Phase I trial showing early promising... 
Via Benzinga
Exposures Product Safety
EXCLUSIVE: Anixa Biosciences Finds Stock Undervalued, Launches $5M Stock Buyback Program
Anixa Biosciences announces $5 million share repurchase program due to undervalued stock. Partnership with Cleveland Clinic for cancer vaccines. 
Via Benzinga
ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024
ANIX stock results show that Anixa Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
7 Penny Biotech Stocks to Triple Your Investment
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns. 
Via InvestorPlace
Anixa Biosciences, A New Type Of Biotech Company: Could It Disrupt The Cancer Landscape?
Anixa Biosciences (NASDAQ: ANIX) is an interesting, undiscovered biotech company that seeks to disrupt the cancer landscape by working with some highly credible partners. The company is undiscovered... 
Via Benzinga
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider. 
Via InvestorPlace
Anixa Biosciences Reveals Updated Data From Breast Cancer Vaccine Trial, Says 'Exceeded Expectations'
Anixa Biosciences Inc (NASDAQ: ANIX) announced new and updated results from the Phase 1 trial of its breast cancer vaccine.  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
The 3 Most Undervalued Cheap Stocks to Buy in September 2023
These cheap stocks to buy are the ones for long term growth and high returns in your investment portfolio. 
Via InvestorPlace
Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the... 
Via Benzinga
Anixa Biosciences And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones edged higher on Friday, recording gains for the tenth straight session. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Appreciating The Passing Of A Titan & Incorporating Alternative Data Signals
Kathleen Moriarty, the lawyer who helped develop the structure for SPY and a true co-founder of the ETF industry, passed away last week. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 23, 2022
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares increased by 12.7% to $0.34 during Monday's after-market session. The market value of their outstanding shares is at $1.2 million. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday. 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.